

FORM PTO-1449/A and B (modified PTO/SB/08)  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				APPLICATION NO.: 10/541,708		ATTY. DOCKET NO.: A0848.70010US00	
				FILING DATE: July 8, 2005		CONFIRMATION NO.: 6032	
				APPLICANT: Karen Silence			
				GROUP ART UNIT: 1644		EXAMINER: Szperka, Michael Edward	
Sheet	1	of	1				

## U.S. PATENT DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/MS/	A9	6,759,518		Kontermann et al.	07-06-2004
/MS/	A10	2002/0058033	A1	Raisch et al.	05-16-2002
/MS/	A11	2003/0092892	A1	Frenken et al.	05-15-2003

## FOREIGN PATENT DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
/MS/	B17	EP	0 952 218	A2	Hoechst Marion Roussel Deutschland GmbH	10-27-1999	

## OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials <sup>a</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/MS/	C16	D'HAENS, G. et al. "Endoscopic and Histological Healing With Infliximab Anti-Tumor Necrosis Factor Antibodies in Crohn's Disease: A European Multicenter Trial," <i>Gastroenterology</i> 1999; 116(5):1029-1034	
	C17	HOLLIGER, P. et al. "Retargeting serum immunoglobulin with bispecific diabodies," <i>Nature Biotechnology</i> 1997 July; 15:632-636	
	C18	HOOGENBOOM, H.R. "Mix and match: Building manifold binding sites," <i>Nature Biotechnology</i> 1999 Feb.; 15:125-126	
/MS/	C19	NERI, D. et al. "High-affinity Antigen Binding by Chelating Recombinant Antibodies (CRAbs)," <i>J. Mol. Biol.</i> 1995; 246:367-373	

<sup>a</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

/Michael Szperka/

11/24/2008